Competitive Salary: University of Nebraska Medical Center: The Dept. of Genetics, Cell Biology and Anatomy seeks an Assistant/Associate Professor with expertise in ‘Bioinformatics and Human Microbiome’. Omaha, Nebraska

Notice NOT-AA-19-015 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-044 from the NIH Guide for Grants and Contracts

Notice NOT-HL-19-695 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-GM-19-001 from the NIH Guide for Grants and Contracts. Human induced pluripotent stem cells (iPSCs) have been used with great success to mimic the differentiation of a variety of tissues, understand early development and study human diseases. Despite approaches that have made the derivation, growth and differentiation of iPSCs more efficient, there remains significant variability in reprogramming efficacy, genomic integrity and developmental potential of iPSCs derived from a single fibroblast or tissue sample. Thus, iPSCs derived from the same sample may differ in their in vitro growth characteristics and their ability to re-differentiate into the desired tissue type. A variety of issues may affect derivation of the iPSCs and their growth, stability and differentiation, including the specific characteristics of the starting cell or tissue sample (e.g., age of donor, tissue type and anatomical location, physiological and disease state), the methods and protocols used to induce pluripotency (e.g., transcription factors, small molecules, cell fusion), the choice of growth factors and other culture conditions, method of storage of cell lines, etc. Further challenges include growing and maintaining sufficient quantities of iPSC lines in culture without changes in their properties, as well as the ability of multiple investigators to identify and authenticate iPSC lines as part of their research. This Funding Opportunity Announcement (FOA) will support SBIR projects to develop novel, reliable and cost-effective methods to standardize and increase the utility and reproducibility of iPSCs at all stages, from their derivation to their research and clinical applications.

Notice NOT-OD-19-108 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-TR-19-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.

Funding Opportunity PAR-19-286 from the NIH Guide for Grants and Contracts. The NIGMS Postdoctoral Research Associate Training (PRAT) Programs overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences to a diverse group of postdoctoral fellows in NIH Intramural research laboratories, and to prepare them for leadership positions in biomedical careers. Research projects proposed should focus on areas within the NIGMS mission, which include but are not limited to biological chemistry, biophysics, bioinformatics, cellular and molecular biology, computational biosciences, developmental biology, genetics, immunology, neuroscience, pharmacology, physiology, and technology development. In addition to the laboratory experience, the PRAT program provides a structured training environment with extensive career and professional development, mentoring, and networking opportunities planned and supported by the program.

Orion Corporation: Orion Corporation is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and market Finland (FI)

Notice NOT-DA-19-046 from the NIH Guide for Grants and Contracts

Competitive + Excellent Benefits: AstraZeneca - Cambridge: At AstraZeneca, we turn ideas into life changing medicines. Working here means being entrepreneurial, thinking big and working together Cambridge, Cambridgeshire

Competitive Salary: EMBL: Ensembl Comparative Genomics Project Leader Location Cambridge, Cambridgeshire, England

£30,042 to £39,640 per annum: National Institute of Agricultural Botany (NIAB): We are looking for an enthusiastic and talented bioinformatician/quantitative geneticist to work on the genetics of wheat yellow rust resistance Cambridge, Cambridgeshire

This project will provide the selected candidate with experience and training in plant molecular biology and genetics, generation of transgenic plants, and... $5,185 a month
From Oak Ridge Associated Universities - Fri, 17 May 2019 20:17:03 GMT - View all Madison, WI jobs

Funding Opportunity RFA-RM-19-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that propose to establish Offices of Sponsored Programs (OSPs) or enhance the services of existing OSPs or similar entities at domestic institutions of higher learning. Program priorities include funding primarily undergraduate institutions with emerging biomedical research and/or undergraduate research training programs.

Notice NOT-OD-19-110 from the NIH Guide for Grants and Contracts

Competitive salary + Pension, Health insurance, Gym, Bonus, Shares: Illumina: You will work on algorithms and methods in bioinformatics, machine learning, signal processing, and develop workflows and programming interfaces. Great Abington, Cambridge

Notice NOT-NS-19-059 from the NIH Guide for Grants and Contracts

Orion Corporation: Orion Corporation is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and market Finland (FI)

Orion Corporation: Orion Corporation is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and market Finland (FI)